Stan Hollenbach joins Ambys with over 30 years of experience in biotechnology and pharmacology, most recently at Novan, where he served as senior vice president of research and development. Prior to Novan, Stan spent 10 years at Portola Pharmaceuticals, where he was vice president of pharmacology. Stan previously held positions at Millennium Pharmaceuticals, COR Therapeutics, and Genentech, and he has participated in the advancement of several successful preclinical development programs (thrombolytic agents, thrombin, Factor Xa, GP IIb-IIIa, and kinase inhibitors) to an IND or NDA status. Over his 24 years with COR Therapeutics, Millennium, and then Portola, Stan built and established an in vivo pharmacology program with extensive capacity to evaluate the pharmacokinetics, pharmacodynamics, toxicology, and efficacy profile of new therapeutic agents in multiple large and small animal species, with a specialty in venous and arterial thrombosis models.
Stan holds a B.S. from the University of North Carolina, Charlotte and a J.D. from Peninsula University.